Literature DB >> 16489109

LRP and alphavbeta3 mediate tPA activation of smooth muscle cells.

Sa'ed Akkawi1, Taher Nassar, Mark Tarshis, Douglas B Cines, Abd Al-Roof Higazi.   

Abstract

Tissue-type plasminogen activator (tPA) regulates vascular contractility through the low-density lipoprotein-related receptor (LRP), and this effect is inhibited by plasminogen activator inhibitor type 1 (PAI-1). We now report that tPA-mediated vasocontraction also requires the integrin alphavbeta3. tPA-induced contraction of rat aortic rings is inhibited by the Arg-Gly-Asp (RGD) peptide and by monoclonal anti-alphavbeta3 antibody. tPA induces the formation of a complex between LRP and alphavbeta3 in vascular smooth muscle cells. The three proteins are internalized within 10 min, causing the cells to become refractory to the readdition of tPA. LRP and alphavbeta3 return to the cell surface by 90 min, restoring cell responsiveness to tPA. PAI-1 and the PAI-1-derived hexapeptide EEIIMD abolish the vasocontractile activity of tPA and inhibit the tPA-mediated interaction between LRP and alphavbeta3. tPA induces calcium mobilization from intracellular stores in vascular smooth muscle cells, and this effect is inhibited by PAI-1, RGD, and antibodies to both LRP and alphavbeta3. These data indicate that tPA-mediated vasocontraction involves the coordinated interaction of LRP with alphavbeta3. Delineating the mechanism underlying these interactions and the nature of the signals transduced may provide new tools to regulate vascular tone and other consequences of tPA-mediated signaling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16489109     DOI: 10.1152/ajpheart.01042.2005

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  31 in total

1.  Signaling through LRP1: Protection from atherosclerosis and beyond.

Authors:  Philippe Boucher; Joachim Herz
Journal:  Biochem Pharmacol       Date:  2010-10-30       Impact factor: 5.858

2.  Novel plasminogen activator inhibitor-1-derived peptide protects against impairment of cerebrovasodilation after photothrombosis through inhibition of JNK MAPK.

Authors:  William M Armstead; John Riley; J Willis Kiessling; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-06-10       Impact factor: 3.619

3.  tPA activates LDL receptor-related protein 1-mediated mitogenic signaling involving the p90RSK and GSK3beta pathway.

Authors:  Ling Lin; Guojun Bu; Wendy M Mars; W Brian Reeves; Sakae Tanaka; Kebin Hu
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

4.  Combination therapy with glucagon and a novel plasminogen activator inhibitor-1-derived peptide enhances protection against impaired cerebrovasodilation during hypotension after traumatic brain injury through inhibition of ERK and JNK MAPK.

Authors:  William M Armstead; John Riley; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Neurol Res       Date:  2012-05-30       Impact factor: 2.448

5.  tPA contributes to impaired NMDA cerebrovasodilation after traumatic brain injury through activation of JNK MAPK.

Authors:  William M Armstead; J Willis Kiessling; John Riley; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Neurol Res       Date:  2011-09       Impact factor: 2.448

6.  Constriction of carotid arteries by urokinase-type plasminogen activator requires catalytic activity and is independent of NH(2)-terminal domains.

Authors:  Philip G Massey; Shinji Tanaka; Joshua M Buckler; Bo Jiang; Anton McCourtie; Kun Qian; Clifford Tom; April Stempien-Otero; Shan Wen; Ian Luttrell; Kanchan Chitaley; David A Dichek
Journal:  Thromb Haemost       Date:  2009-11       Impact factor: 5.249

7.  PAI-1-derived peptide EEIIMD prevents impairment of cerebrovasodilation by augmenting p38 MAPK upregulation after cerebral hypoxia/ischemia.

Authors:  William M Armstead; John Riley; J Willis Kiessling; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-30       Impact factor: 4.733

8.  Urokinase plasminogen activator regulates pulmonary arterial contractility and vascular permeability in mice.

Authors:  Taher Nassar; Serge Yarovoi; Rami Abu Fanne; Otailah Waked; Timothy C Allen; Steven Idell; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Am J Respir Cell Mol Biol       Date:  2011-05-26       Impact factor: 6.914

Review 9.  Tissue-type plasminogen activator as a therapeutic target in stroke.

Authors:  Iordanis Gravanis; Stella E Tsirka
Journal:  Expert Opin Ther Targets       Date:  2008-02       Impact factor: 6.902

10.  uPA modulates the age-dependent effect of brain injury on cerebral hemodynamics through LRP and ERK MAPK.

Authors:  William M Armstead; Douglas B Cines; Khalil H Bdeir; Yasmina Bdeir; Sherman C Stein; Abd Al-Roof Higazi
Journal:  J Cereb Blood Flow Metab       Date:  2008-12-03       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.